E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 27.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052362 |
E.1.2 | Term | Metastatic colorectal cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Phase I: To determine the maximum tolerated dose of 5-Fluorouracil 24-hour EPIC, in combination with intensified oxaliplatin/irinotecan HIPEC, for treatment of colorectal cancer.
Phase III: To study the recurrence-free survival (RFS) of patients within 24 months
|
|
E.2.2 | Secondary objectives of the trial |
1. Overall and recurrence-free survival up to 5 years 2. Postoperative complication rates within 30 days 3. Quality of life of patients up to 3 years after study treatment
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provision of written informed consent prior to any study specific procedures. 2. ECOG Performance Status Score 0,1 or 2, alternatively Karnofsky 60-100 3. Adequate kidney, liver, bone marrow function according to laboratory tests. 4. For females of childbearing potential, a negative pregnancy test must be documented. 5. ≥ 18 years old and <=78 years old. 6. Colorectal cancer with peritoneal metastases +/- liver metastases 7. Concomitant resectable pulmonary metastases 7. All patients deemed eligible for CRS and HIPEC according to clinical routine
|
|
E.4 | Principal exclusion criteria |
1. Previous severe toxicity/allergic reactions to systemic chemotherapy agents oxaliplatin or irinotecan or 5-fluorouracil 2. Unable to tolerate intensified HIPEC treatment due to comorbidity 3. Metastasis other than peritoneum or liver or lung (ie paraaortal lymph node or bone metastases) 4. Previous CRS or HIPEC 5. Pregnant or lactating (nursing) women 6. Active infections requiring antibiotics 7. Active liver disease with positive serology for active hepatitis B, C, or known HIV 8. Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to and up to 4 weeks after study treatment 9. Incomplete cytoreduction defined as completeness of cytoreduction score 2-3 10. Histopathology of other origin than colorectal cancer
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Phase I: Maximum tolerated dose of 5-FU 24-hour EPIC. Possible toxicity will be reported as Adverse Events.
Phase III: Local control rate within 24 months – Defined as peritoneal or liver recurrence. Retroperitoneal llg not included in this definition
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Phase I: 30 days post-treatment
Phase III: within 24 months |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints are to evaluate the: • Overall survival and RFS up to 5 years through the HIPEC registry • Postoperative complication rates within 30 days • Quality of life of patients up to 3 years after treatment
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
RFS is assessed 1 year, 3 years and 5 years after treatment. Overall survival is assessed 5 years after treatment. Postoperative complication rates are followed for 30 days. QoL questionnaires are filled out at baseline and 12 and 36 months after surgery. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
To evaluate maximum tolerated dose of 5-fluorouracil |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject, follow-up is registry-based |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |